-
Product Insights
Irritable Bowel Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Irritable Bowel Syndrome - Drugs In Development, 2023’, provides an overview of the Irritable Bowel Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NOV-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NOV-001 Drug Details NOV-001 is under development for the treatment of secondary hyperoxaluria. They...
-
Product Insights
Irritable Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of irritable bowel syndrome include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite, and constipation. These symptoms can be triggered by food, stress, and hormones. The Irritable Bowel Syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis – Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer,...